Join Dr Alexander Cohen for a discussion of his study: Comparison of fatal or irreversible events with extended‐duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX trial substudy
Speaker
Guy's and St Thomas’ Hospitals
London, UK
Topic
Patients who are hospitalised for acute medical illnesses are at an increased risk for venous thromboembolism. Betrixaban recently became the first NOAC to receive approval for extended-duration thromboprophylaxis after hospital discharge in this patient population. In this journal club, we take a look at the most recent post-hoc analysis to emerge from the APEX trial, which considers the impact of betrixaban on fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin.
View abstract access full paper
-
Target audience
This educational activity is designed for hospitalists, haematologists, interventional cardiologists, internists, surgeons, and any other healthcare professional with an interest or role in thromboprophylaxis or the management of the acutely medically ill.
-
Learning objectives
After completing this educational activity, participants should be able to:
- Recall the rate of irreversible ischaemic or bleeding events with extended-duration betrixaban compared with enoxaparin in hospitalised, medically ill patients
-
Disclosures
PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
-
Funding
This independent educational activity is supported by funding from Portola Pharmaceuticals. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run independently of the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.
